For General Information, page-2328

Arjay
Sareptas drug for Limb girdle has many obstacles to overcome and far to expensive to manufacture


SRP-9003 is a gene therapy for limb girdle type 2E/R4 related to the loss of betasarcoglycan.
That’s a different limb girdle disease to Anp’s Limb Girdle type R2 related to the loss of dysferlin

I don’t think Sarepta will actually move a gene therapy into Limb Girdle type R2 because of the science .
LGMDR2 is related to dysferlin loss in muscle and dysferlin loss also activates macrophages, and Anp is targeting the immune component…..

This is why I’m calling $5 in time

Anp will get Limb Girdle to market first ( No real competitors)